Among the stages of the HIV life cycle, viral entry is an attractive target for the design of new therapeutic agents. The principle purpose of this project is to design and characterize an efficient entry inhibitor. Additionally we have attempted to define the basic biochemical requirements necessary for efficient inhibition of HIV-1 entry into primary CD4+ T-cells. Such information should be generally useful in the design of entry inhibitors. Soluble (s) CD4, the first entry inhibitor to be tested clinically, failed primarily because it demonstrated poor neutralizing activity against primary isolates of HIV-1. In addition, sCD4 manifested an intrinsic capacity to enhance viral replication at low concentrations. To overcome the deficiencies associated with monomeric sCD4 we fused the envelope binding domain of CD4 (D1D2) to Ig-alpha-tp creating a recombinant protein we term D1D2-Ig-alpha-tp . This recombinant protein exhibited a mass greater than 650 kilodaltons (kDa) and present twelve gp120 binding sites. The presentation of twelve closely spaced gp120 binding sites should improve the capacity of sCD4 to compete with membrane CD4 for virion associated gp120. In addition, the extremely large size of this protein should preclude any interaction between activated virion spikes and CCR5, the important co-receptor for most primary HIV infections, on the target cell membrane. We have expressed and characterized this protein in vitro and have found that it exhibits an extraordinarily high affinity for the envelopes of primary HIV-1 isolates. Importantly it efficiently inhibits the replication of virus from HIV-1 positive patient PBMCs. In viral neutralization assays D1D2-Ig-alpha-tp inhibits viral replication at levels comparable to the most potent neutralizing antibodies available. Moreover, unlike monomeric sCD4, at suboptimal concentrations this recombinant protein show no entry-enhancing activity. Each of these activities suggest that we have progressed significantly in our principle goals. Based on these observations we are evaluating D1D2-Ig-alpha-tp as a potential therapeutic agent and a potential adjuvant vaccine strategy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Intramural Research (Z01)
Project #
1Z01AI000883-02
Application #
6669884
Study Section
(LIR)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Wang, Shixia; Kennedy, Jeffrey S; West, Kim et al. (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:3947-57
Garron, Marie-Line; Arthos, James; Guichou, Jean-Francois et al. (2008) Structural basis for the interaction between focal adhesion kinase and CD4. J Mol Biol 375:1320-8
Arthos, James; Cicala, Claudia; Martinelli, Elena et al. (2008) HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 9:301-9
Wang, Shixia; Kennedy, Jeffrey S; West, Kim et al. (2008) Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:1098-110
Martinelli, Elena; Cicala, Claudia; Van Ryk, Donald et al. (2007) HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 104:3396-401
Bennett, Adam; Liu, Jun; Van Ryk, Donald et al. (2007) Cryoelectron tomographic analysis of an HIV-neutralizing protein and its complex with native viral gp120. J Biol Chem 282:27754-9
Kottilil, Shyam; Jackson, Julia O; Reitano, Kristin N et al. (2007) Innate immunity in HIV infection: enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia. J Acquir Immune Defic Syndr 46:151-9
Zhou, Tongqing; Xu, Ling; Dey, Barna et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-7
Cocklin, Simon; Gopi, Hosahudya; Querido, Bianca et al. (2007) Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor. J Virol 81:3645-8
Cicala, Claudia; Arthos, James; Censoplano, Nina et al. (2006) HIV-1 gp120 induces NFAT nuclear translocation in resting CD4+ T-cells. Virology 345:105-14

Showing the most recent 10 out of 22 publications